Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Oraxol (Paclitaxel + HM30181A) in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies

NCT03588039 is registered in ClinicalTrials.gov with Athenex, Inc. as lead sponsor.

NCT NCT03588039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03588039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Oraxol (Paclitaxel + HM30181A) in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
Lead sponsor
Athenex, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 25, 2018
Completion date
May 12, 2023
Enrollment
34 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor